Literature DB >> 21080003

Uraemic vasculopathy in children with chronic kidney disease: prevention or damage limitation?

Rukshana Shroff1, Catherine Quinlan, Mark Mitsnefes.   

Abstract

Since the inception of pediatric dialysis programmes nearly 50 years ago, there have been vast improvements in both the technology and expertise in the care of children with chronic kidney disease (CKD). Nevertheless, children on dialysis continue to have a significantly higher mortality than their healthy peers and cardiovascular disease (CVD) is the most common cause of death in this group. Chronic kidney disease is described as the "perfect storm" of risk factors for CVD development, and vascular calcification is a highly regulated cell-mediated process with several promoters and inhibitors of calcification. CVD begins early in the course of CKD and there is an independent and graded association between cardiovascular morbidity and renal decline. Also, it is shown that once vascular damage and calcification begin, they progress inexorably in the uraemic milieu and may only be partially reversed after successful transplantation. Thus, preventing the development of CVD is key, and early identification and management of specific CVD-related risk factors should begin from the early stages of CKD. While the vasculopathy of childhood CKD is clearly multifactorial, clinical, epidemiological and cell biology studies provide converging evidence pointing to the role of dysregulated mineral metabolism as an important modifiable risk factor in the development of vascular calcification. In this review we focus on the role of calcium, phosphate, parathyroid hormone and vitamin D in ectopic vascular calcification, and discuss the role of screening, early intervention and management of established vascular calcification.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21080003     DOI: 10.1007/s00467-010-1691-y

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN: 0931-041X            Impact factor:   3.714


  103 in total

1.  Associations of coronary heart disease risk factors with the intermediate lesion of atherosclerosis in youth. The Pathobiological Determinants of Atherosclerosis in Youth (PDAY) Research Group.

Authors:  H C McGill; C A McMahan; A W Zieske; G D Sloop; J V Walcott; D A Troxclair; G T Malcom; R E Tracy; M C Oalmann; J P Strong
Journal:  Arterioscler Thromb Vasc Biol       Date:  2000-08       Impact factor: 8.311

2.  Novel conformation-specific antibodies against matrix gamma-carboxyglutamic acid (Gla) protein: undercarboxylated matrix Gla protein as marker for vascular calcification.

Authors:  Leon J Schurgers; Kirsten J F Teunissen; Marjo H J Knapen; Martijn Kwaijtaal; Rob van Diest; Ad Appels; Chris P Reutelingsperger; Jack P M Cleutjens; Cees Vermeer
Journal:  Arterioscler Thromb Vasc Biol       Date:  2005-06-16       Impact factor: 8.311

3.  Association of hypertriglyceridemia and insulin resistance in uremic patients undergoing CAPD.

Authors:  S C Cheng; T S Chu; K Y Huang; Y M Chen; W K Chang; T J Tsai; K D Wu
Journal:  Perit Dial Int       Date:  2001 May-Jun       Impact factor: 1.756

4.  Controlling the epidemic of cardiovascular disease in chronic renal disease: what do we know? What do we need to learn? Where do we go from here? National Kidney Foundation Task Force on Cardiovascular Disease.

Authors:  A S Levey; J A Beto; B E Coronado; G Eknoyan; R N Foley; B L Kasiske; M J Klag; L U Mailloux; C L Manske; K B Meyer; P S Parfrey; M A Pfeffer; N K Wenger; P W Wilson; J T Wright
Journal:  Am J Kidney Dis       Date:  1998-11       Impact factor: 8.860

5.  Evolution of large-vessel arteriopathy in paediatric patients with chronic kidney disease.

Authors:  Mieczyslaw Litwin; Elke Wühl; Claudia Jourdan; Anna Niemirska; Jens P Schenk; Katarzyna Jobs; Ryszard Grenda; Zbigniew T Wawer; Pawel Rajszys; Otto Mehls; Franz Schaefer
Journal:  Nephrol Dial Transplant       Date:  2008-03-14       Impact factor: 5.992

6.  Phosphorus binders and survival on hemodialysis.

Authors:  Tamara Isakova; Orlando M Gutiérrez; Yuchiao Chang; Anand Shah; Hector Tamez; Kelsey Smith; Ravi Thadhani; Myles Wolf
Journal:  J Am Soc Nephrol       Date:  2008-12-17       Impact factor: 10.121

7.  Increased arterial stiffness in young adults with end-stage renal disease since childhood.

Authors:  Jaap W Groothoff; Mariken P Gruppen; Martin Offringa; Eric de Groot; Willem Stok; Willem Jan Bos; Jean Claude Davin; Marc R Lilien; Nicole Caj Van de Kar; Eric D Wolff; Hugo S Heymans
Journal:  J Am Soc Nephrol       Date:  2002-12       Impact factor: 10.121

8.  Vitamin D analogs for secondary hyperparathyroidism: what does the future hold?

Authors:  Alex J Brown
Journal:  J Steroid Biochem Mol Biol       Date:  2006-12-27       Impact factor: 4.292

9.  Dialysis accelerates medial vascular calcification in part by triggering smooth muscle cell apoptosis.

Authors:  Rukshana C Shroff; Rosamund McNair; Nichola Figg; Jeremy N Skepper; Leon Schurgers; Ashmeet Gupta; Melanie Hiorns; Ann E Donald; John Deanfield; Lesley Rees; Catherine M Shanahan
Journal:  Circulation       Date:  2008-10-06       Impact factor: 29.690

10.  Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease.

Authors:  Orlando M Gutiérrez; James L Januzzi; Tamara Isakova; Karen Laliberte; Kelsey Smith; Gina Collerone; Ammar Sarwar; Udo Hoffmann; Erin Coglianese; Robert Christenson; Thomas J Wang; Christopher deFilippi; Myles Wolf
Journal:  Circulation       Date:  2009-05-04       Impact factor: 29.690

View more
  13 in total

Review 1.  Intensified hemodialysis in adults, and in children and adolescents.

Authors:  Julia Thumfart; Wolfgang Pommer; Uwe Querfeld; Dominik Müller
Journal:  Dtsch Arztebl Int       Date:  2014-04-04       Impact factor: 5.594

2.  Glucose intolerance: is it a risk factor for cardiovascular disease in children with chronic kidney disease?

Authors:  Nur Canpolat; Salim Caliskan; Lale Sever; Alper Guzeltas; Fatih Kantarci; Cengiz Candan; Mahmut Civilibal; Ozgur Kasapcopur; Nil Arisoy
Journal:  Pediatr Nephrol       Date:  2011-10-08       Impact factor: 3.714

Review 3.  Why are kids with lupus at an increased risk of cardiovascular disease?

Authors:  Catherine Quinlan; Stephen D Marks; Kjell Tullus
Journal:  Pediatr Nephrol       Date:  2015-09-23       Impact factor: 3.714

Review 4.  Cardiovascular complications in children with chronic kidney disease.

Authors:  Rukshana Shroff; Donald J Weaver; Mark M Mitsnefes
Journal:  Nat Rev Nephrol       Date:  2011-09-13       Impact factor: 28.314

Review 5.  Phosphate is a vascular toxin.

Authors:  Rukshana Shroff
Journal:  Pediatr Nephrol       Date:  2012-11-17       Impact factor: 3.714

6.  Intima media thickness in children undergoing dialysis.

Authors:  Luis Antonio Chavarria; Alejandra Aguilar-Kitsu; Patricia Rosas; Arturo Fajardo; Leticia Mendoza-Guevara; Lorena Sanchez; Claudia Zepeda; Pilar Ibarra; Alejandro Luna; Bengt Lindholm; Elvia García-López
Journal:  Pediatr Nephrol       Date:  2012-05-03       Impact factor: 3.714

7.  Interdialytic weight gain and vasculopathy in children on hemodialysis: a single center study.

Authors:  Vasiliki Karava; Cherine Benzouid; Theresa Kwon; Marie-Alice Macher; Georges Deschênes; Julien Hogan
Journal:  Pediatr Nephrol       Date:  2018-09-03       Impact factor: 3.714

Review 8.  Cardiovascular risk assessment in children with chronic kidney disease.

Authors:  Rukshana Shroff; Arianna Dégi; Andrea Kerti; Eva Kis; Orsolya Cseprekál; Kálmán Tory; Attila J Szabó; George S Reusz
Journal:  Pediatr Nephrol       Date:  2012-10-16       Impact factor: 3.714

Review 9.  Nocturnal intermittent hemodialysis.

Authors:  Julia Thumfart; Dominik Müller
Journal:  Pediatr Nephrol       Date:  2014-08-08       Impact factor: 3.714

10.  Malnutrition and its association with inflammation and vascular disease in children on maintenance dialysis.

Authors:  Nur Canpolat; Salim Caliskan; Lale Sever; Mehmet Tasdemir; Ozlem Balcı Ekmekci; Gulseren Pehlivan; Rukshana Shroff
Journal:  Pediatr Nephrol       Date:  2013-06-14       Impact factor: 3.714

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.